3月2日，医药领域迎来暖意融融的好消息，多家药企集中发布公告，披露创新药研发与审批的重大进展，涉及新适应证获批、突破性疗法认定、临床许可等。这些成果彰显了我国医药创新的强劲活力。其中3月2日，信达生物与礼来中国共同宣布，非共价(可逆)BTK抑制剂捷帕力(匹妥布替尼)正式获得国家药监局批准新增适应症，用于治疗既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病(...
Source Link3月2日，医药领域迎来暖意融融的好消息，多家药企集中发布公告，披露创新药研发与审批的重大进展，涉及新适应证获批、突破性疗法认定、临床许可等。这些成果彰显了我国医药创新的强劲活力。其中3月2日，信达生物与礼来中国共同宣布，非共价(可逆)BTK抑制剂捷帕力(匹妥布替尼)正式获得国家药监局批准新增适应症，用于治疗既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.